Hsbc Holdings PLC Purchases New Stake in InfuSystem Holdings, Inc. $INFU

Key Points

• Hsbc Holdings PLC acquired 27,026 shares of InfuSystem Holdings, Inc. during the 1st quarter, amounting to a stake valued at approximately $147,000, representing 0.13% of the company.
• Significant increases in ownership were seen among other institutional investors, with Nuveen Asset Management raising their stake by 14.1%, and Deutsche Bank AG increasing theirs by 148.3% in the fourth quarter.
• InfuSystem has a current market capitalization of $207.53 million and an average analyst rating of "Strong Buy" with a projected price target of $12.50.

Hsbc Holdings PLC bought a new stake in InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 27,026 shares of the company's stock, valued at approximately $147,000. Hsbc Holdings PLC owned approximately 0.13% of InfuSystem at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. BNP Paribas Financial Markets grew its stake in shares of InfuSystem by 67.9% in the 4th quarter. BNP Paribas Financial Markets now owns 6,844 shares of the company's stock valued at $58,000 after purchasing an additional 2,768 shares during the period. Wells Fargo & Company MN boosted its stake in InfuSystem by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,286 shares of the company's stock valued at $78,000 after buying an additional 3,165 shares in the last quarter. MetLife Investment Management LLC bought a new stake in InfuSystem in the fourth quarter valued at $110,000. Virtu Financial LLC bought a new stake in InfuSystem in the first quarter valued at $86,000. Finally, Salem Investment Counselors Inc. acquired a new position in InfuSystem during the first quarter worth $121,000. 71.13% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

INFU has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of InfuSystem from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, May 14th. Roth Capital assumed coverage on shares of InfuSystem in a research report on Tuesday, July 22nd. They issued a "buy" rating and a $12.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, InfuSystem presently has a consensus rating of "Strong Buy" and a consensus price target of $12.50.

Insider Transactions at InfuSystem

In related news, Director Scott Shuda sold 5,752 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $9.67, for a total value of $55,621.84. Following the transaction, the director owned 94,000 shares in the company, valued at $908,980. This trade represents a 5.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.40% of the stock is currently owned by corporate insiders.

InfuSystem Price Performance

Shares of NYSE:INFU traded up $0.16 during midday trading on Tuesday, reaching $10.42. The company's stock had a trading volume of 316,773 shares, compared to its average volume of 179,389. InfuSystem Holdings, Inc. has a fifty-two week low of $4.61 and a fifty-two week high of $11.04. The company has a market capitalization of $212.84 million, a P/E ratio of 173.70 and a beta of 1.82. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59. The business's fifty day simple moving average is $7.70 and its 200-day simple moving average is $6.41.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.